⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744408 | 0.78 | — | — | |
| SCHEMBL548341 | 0.67 | — | — | |
| SCHEMBL16689074 | 0.65 | CA1 (0.38) | — | |
| SCHEMBL27672482 | 0.65 | CA1 (0.38) | — | |
| SCHEMBL16689076 | 0.65 | CA1 (0.38) | — | |
| Butyrolactone SCHEMBL27785508 | 0.61 | — | — | |
| SCHEMBL498251 | 0.61 | — | — | |
| Butyrolactone SCHEMBL1271043 | 0.60 | CA1 (0.82) | — | |
| SCHEMBL89286 | 0.60 | — | — | |
| SCHEMBL2081006 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092764-A1 | KINASE INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2024-03-21 | — | — | US | claimed |
| US-20240092765-A1 | METHODS OF INHIBITING KINASES | INSILICO MEDICINE IP LIMITED (HK) | 2024-03-21 | — | — | US | claimed |
| US-11795160-B2 | Kinase inhibitors | INSILICO MEDICINE IP LIMITED (HK) | 2023-10-24 | — | — | US | claimed |
| US-11739078-B2 | Methods of inhibiting kinases | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-29 | — | — | US | claimed |
| CN-116199643-A | Phenothiazine compound containing isopropanol substructure, and preparation and application thereof | 贵州大学 | 2023-06-02 | — | — | CN | claimed |
| CN-116041308-A | Seven-membered cyclic saccharide compound, and preparation method and application thereof | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2023-05-02 | — | — | CN | claimed |
| CN-113924295-A | Kinase inhibitors | 英矽智能科技知识产权有限公司 | 2022-01-11 | — | — | CN | claimed |
| EP-3927700-A1 | KINASE INHIBITORS | Insilico Medicine IP Limited (HK) | 2021-12-29 | — | — | EP | claimed |
| CN-113461634-A | Thiazole hydrazide compounds and preparation method and application thereof | 贵州大学 | 2021-10-01 | — | — | CN | claimed |
| CN-109641906-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2021-10-01 | — | — | CN | claimed |
| US-20200270231-A1 | METHODS OF INHIBITING KINASES | INSILICO MEDICINE IP LIMITED (HK) | 2020-08-27 | — | — | US | claimed |
| US-20200270234-A1 | KINASE INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2020-08-27 | — | — | US | claimed |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | claimed |
| EP-3475270-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | claimed |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | claimed |
| EP-3475270-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-01 | — | — | EP | claimed |
| WO-2016210036-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | claimed |
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | REJUVERON TELOMERE THERAPEUTICS AG (CH) | 2024-04-23 | — | — | US | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| WO-1994027947-A1 | PHENYLCYCLOPROPANE COMPOUNDS AND THEIR USE AS cAMP AND TNF INHIBITORS | RHONE-POULENC RORER LTD. (GB) | 1994-12-08 | — | — | WO | disclosed |